Compare NEON & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | NRSN |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | Sweden | Israel |
| Employees | N/A | 15 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 24.4M |
| IPO Year | 1994 | N/A |
| Metric | NEON | NRSN |
|---|---|---|
| Price | $1.40 | $0.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $8.50 |
| AVG Volume (30 Days) | 99.6K | ★ 184.0K |
| Earning Date | 05-13-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,108,000.00 | N/A |
| Revenue This Year | $72.74 | N/A |
| Revenue Next Year | $28.94 | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $0.63 |
| 52 Week High | $29.90 | $2.60 |
| Indicator | NEON | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 37.54 |
| Support Level | $1.27 | $0.66 |
| Resistance Level | $2.04 | $1.30 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 54.90 | 30.48 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.